Cisiv secures investment to accelerate growth

We are thrilled to announce a joint investment from Abbey International Finance and Ryan Group Holdings.

The investment will accelerate the expansion of our platform, Baseline Plus, and support Cisiv’s journey to deliver the best technology for Real World Data (RWD) collection.

Our platform, developed for post-approval, provides efficient solutions to the various challenges of gathering prospective observational and primary data in a real-world setting and has become the solution of choice for many large pharmaceutical manufacturers and CROs.

Baseline Plus is used in a wide range of non-interventional and low interventional activities including orphan drug studies and rare disease registries, health economics and outcomes studies (HEOR), large scale mandated post approval safety studies, managed access programmes, and many other study types and data-related activities across a broad range of therapeutic areas.

Dominic Farmer, CEO and co-founder of Cisiv, commented: “We have seen a transformation of the market and a recognition that technology solutions can help deliver evidence more efficiently.

“We are thrilled to see the uptake of Baseline Plus to enable market access, real-world evidence for health outcomes and patient reported outcomes. This new funding will help us to scale our operations and commercial teams to help deliver real-world data to more life science partners.”

To learn more about Baseline Plus and how we can support you, speak to an expert.

Speak to an expert...

To find out more about the Cisiv technology and how we can help you with your study.